Release 1.9 — 7 October 2026

- Added the Caris primary rectal tumour DNA BAM and regenerated index, with complete scientific-record and public-download verification.
- Documented the custom masked hg38 reference and specimen-level mapping to the 27 March 2024 biopsy.

Release 1.6 — 7 October 2026

- Added my case title, personal website, portrait and short biography, including age at diagnosis and current age.
- Changed my narrative to first person and clarified potential capecitabine and no prior anti-VEGF treatment.
- Removed the evidence-refinement section and corrected relevant treatment-access caveats.
- Ordered the tabs as Overview, Clinical timeline, Reports, Molecular evidence, Sequencing, Pathology, Imaging, and Use & provenance. Sequencing contains DNA and RNA views; laboratory results are within Clinical timeline. Downloads and reports use subtype/type groups followed by providers.

Release 1.6.1 — 7 October 2026

- Replaced the introductory case description and biography with my requested wording.

Release 1.7 — 7 October 2026

- Added Research & documentation after Imaging for my cross-provider research, curated source summaries, inventories and project documentation.
- Moved molecular, imaging, pathology and ctDNA summary tables into the new tab; retained the clinical timeline and laboratory reading views.
- Kept provider-issued reports, original provider expression outputs, sequencing files and images in their source views, grouped by type and provider.

Release 1.8 — 7 October 2026

- Removed duplicate report cards from Molecular evidence; report documents remain in Reports.
- Organized provider-produced variant calls, expression tables, HLA predictions and fusion candidates in Molecular evidence. DNA/RNA reads and alignments remain in Sequencing.
- Kept my cross-provider summaries and documentation in Research & documentation, and preserved provider attribution and original scientific file content.
- Added visible, report-specific results summaries to all 26 report cards, with source page references and pertinent limitations.

Release 1.9 — 7 October 2026

- Added a concise, source-linked therapeutic shortlist to the Overview: eight drug candidates and two separate cellular-therapy options.
- Kept evidence maturity, access limits, prior BOT/BAL uncertainty and patient-specific eligibility constraints visible.
- Preserved the existing treatment plans, detailed candidate cards and all source-report downloads.

Release 1.10 — 8 October 2026

- Consolidated the prior therapeutic cards and shortlist into one table under Potential therapeutics and trials, after the treatment and vaccine plans.
- Added PF-08046050 and established later-line options; merged overlapping entries without duplicate rows.
- Preserved case evidence, detailed eligibility and sequencing notes, and source links in expandable row details.
- Retained the clinical evidence cutoff of 7 October 2026; no new treatment or eligibility outcome is implied.

Release 1.11 — 8 October 2026

- Shortened the Potential therapeutics and trials introduction as requested.

Release 1.12 — 8 October 2026

- Gave established later-line treatments a separate section and table below experimental candidates.
- Shortened the experimental table introduction to Experimental therapeutic candidates.

Release 1.13 — 8 October 2026

- Rebuilt established later-line treatments as seven individual rows with visible case relevance, treatment-specific evidence, UK access and limitations.
- Added oxaliplatin reintroduction, the current irinotecan/panitumumab restart, chemotherapy with bevacizumab, and a separate trifluridine/tipiracil monotherapy option.
- Refreshed randomized evidence and NICE/UK prescribing information; documented additional aflibercept and ramucirumab access limitations.
- Distinguished prior treatment benefit and reintroduction from rechallenge after resistance; retained uncertainty around current neuropathy and informative resistance testing.

Release 1.14 — 8 October 2026

- Shortened section introductions, report summaries, dataset descriptions, timeline entries and treatment-table copy.
- Preserved clinical findings, dates, measurements, specimen links, evidence status, uncertainty and source references.
- Kept report preparation details in full records and corrected the source-inventory availability description.

Release 1.15 — 8 October 2026

- Added robots.txt, a canonical sitemap, AI crawl rules and content-usage signals allowing search, agent input and training for patient-authored content.
- Added a generated Markdown case view containing provider report findings, timeline and dataset metadata, with content negotiation and discovery Link headers.
- Added public OpenAPI/API catalog, ARD catalog aliases, agent research skill discovery with exact digests and read-only WebMCP/MCP research tools.
- Preserved the reviewed clinical records, source IDs, limitations and existing data/PDF downloads.

Release 1.16 — 8 October 2026

- Rebuilt Molecular evidence with report-verified pathogenic, likely pathogenic and VUS sections, source-specific allele fractions and therapy connections.
- Showed each alteration once, retaining differing Caris/Tempus classifications side by side. Put unconfirmed plasma tumour origin and low-purity, post-treatment tissue caveats beside the affected results.
- Added expression and IHC results, immune biomarkers, pertinent pathology and a JLF/Invoke comparison covering all 250 Invoke candidates and all 20 JLF designs.
- Kept provider peptide windows, the CCDC6 RNA discrepancy and ELF3 sequence-context issue explicit; mirrored the summary in the agent-readable case view.
- Changed personal-website links to https://alextisyoung.com/.
